Revision 1

Store at -20C

#88153

VCIP135 Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355) orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H Mk	Endogenous	140	Rabbit	#Q96JH7	80124

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:100

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

VCIP135 Antibody recognizes endogenous levels of total VCIP135 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala1035 of human VCIP135 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Protein ubiquitination and deubiquitination are reversible processes catalyzed by ubiquitinating enzymes and deubiquitinating enzymes, respectively (1,2). Deubiquitinating enzymes (DUBs) are categorized into five subfamilies based on catalytic domain structure: USP, OTU, MJD, and JAMM. The valosin-containing protein p97/p47 complex-interacting protein 1 (VCIP135, VCPIP1) is a deubiquitinating enzyme that belongs to the A20-like subfamily of ovarian tumor (OTU) DUBs (3). VCIP135 serves as a cofactor for the p97/p47 complex in regulating Golgi membrane fusion and reassembly at the end of mitosis (4-6). Research studies suggest that the phosphorylation status of VCIP135 provides a mechanism to fine-tune the kinetics of Golgi disassembly and reassembly during the cell cycle. For example, these studies demonstrate that VCIP135 undergoes phosphorylation early in mitosis, which blocks its association with the Golgi membrane and p97/VCP, thus inhibiting p97/VCP-mediated Golgi membrane fusion (7,8).

Background References

1. Nijman, S.M. et al. (2005) *Cell* 123, 773-86.
2. Nalepa, G. et al. (2006) *Nat Rev Drug Discov* 5, 596-613.
3. Mevissen, T.E. et al. (2013) *Cell* 154, 169-84.
4. Wang, Y. et al. (2004) *J Cell Biol* 164, 973-8.
5. Uchiyama, K. et al. (2002) *J Cell Biol* 159, 855-66.
6. Totsukawa, G. et al. (2011) *EMBO J* 30, 3581-93.
7. Zhang, X. et al. (2014) *J Cell Sci* 127, 172-81.
8. Totsukawa, G. et al. (2013) *Biochem Biophys Res Commun* 433, 237-42.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human **Mk:** Monkey

Trademarks and Patents

Limited Uses

separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.